Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) Return on Equity

The latest ROE for RVPHW is -146.72%. That is below the Healthcare sector average of 22.01%. Investors often review this figure alongside Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, RVPHW currently prints -146.72% for ROE, while the sector average sits near 22.01%. That is roughly 766.6% below the sector mean. Large gaps often invite a closer look at Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Reviva Pharmaceuticals Holdings - Warrants (25/12/2025) converts resources into returns. At -146.72%, RVPHW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RVPHW's ROE (-146.72%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Reviva Pharmaceuticals Holdings - Warrants (25/12/2025)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.